TY - JOUR
T1 - Fluorous-phase iron oxide nanoparticles as enhancers of acoustic droplet vaporization of perfluorocarbons with supra-physiologic boiling point
AU - Vezeridis, Alexander M.
AU - de Gracia Lux, Caroline
AU - Barnhill, Sarah A.
AU - Kim, Sejung
AU - Wu, Zhe
AU - Jin, Sungho
AU - Lux, Jacques
AU - Gianneschi, Nathan C.
AU - Mattrey, Robert F.
N1 - Funding Information:
This work was supported in part by the NIH / NCI-U54-CA119335 and NIH / NCI-P50-CA128346 . Author AMV was supported by the NIH / NCI - R25CA153915 (2012−13) and NIH / NIBIB T32-EB005970 (2013-14). Author RFM was supported in part by the Cancer Prevention Research Institute of Texas (CPRIT) RR150010. The Ultrasound Group of Siemens Medical Solutions USA provided the Sequoia 512 ultrasound scanner as a loaner.
Funding Information:
This work was supported in part by the NIH/NCI-U54-CA119335 and NIH/NCI-P50-CA128346. Author AMV was supported by the NIH/NCI-R25CA153915 (2012−13) and NIH/NIBIB T32-EB005970 (2013-14). Author RFM was supported in part by the Cancer Prevention Research Institute of Texas (CPRIT) RR150010. The Ultrasound Group of Siemens Medical Solutions USA provided the Sequoia 512 ultrasound scanner as a loaner.
Publisher Copyright:
© 2019
PY - 2019/5/28
Y1 - 2019/5/28
N2 - Perfluorocarbon emulsion nanodroplets containing iron oxide nanoparticles (IONPs) within their inner perfluorohexane (PFH) core were prepared to investigate potential use as an acoustically activatable ultrasound contrast agent, with the hypothesis that incorporation of IONPs into the fluorous phase of a liquid perfluorocarbon emulsion would potentiate acoustic vaporization. IONPs with an oleic acid (OA) hydrophobic coating were synthesized through chemical co-precipitation. To suspend IONP in PFH, OA was exchanged with perfluorononanoic acid (PFNA) via ligand exchange to yield fluorophilic PFNA-coated IONPs (PFNA-IONPs). Suspensions with various amounts of PFNA-IONPs (0–15% w/v) in PFH were emulsified in saline by sonication, using 5% (w/v) egg yolk phospholipid as an emulsifier. PFNA-IONPs were characterized with transmission electron microscopy (TEM), transmission electron cryomicroscopy (cryoTEM), and thermogravimetric analysis (TGA) with Fourier transform infrared spectroscopy (FTIR). IONP were between 5 and 10 nm in diameter as measured by electron microscopy, and hydrodynamic size of the PFH nanodroplets were 150 to 230 nm as measured by dynamic light scattering (DLS). Acoustic droplet vaporization of PFH nanodroplets (PFH-NDs) was induced using conversion pulses (100 cycle at 1.1 MHz and 50% duty cycle) provided by a focused ultrasound transducer, and formed microbubbles were imaged using a clinical ultrasound scanner. The acoustic pressure threshold needed for PFH-NDs vaporization decreased with increasing temperature and IONP content. PFH-NDs containing 5% w/v IONP converted to microbubbles at 42 °C at 2.18 MI, which is just above the exposure limits of 1.9 MI allowed by the FDA for clinical ultrasound scanners, whereas 10 and 15% emulsion vaporized at 1.87 and 1.24 MI, respectively. Furthermore, 5% IONP-loaded PFH-NDs injected intravenously into melanoma-bearing mice at a dose of 120 mg PFH/kg, converted into detectable microbubbles in vivo 5 h, but not shortly after injection, indicating that this technique detects NDs accumulated in tumors.
AB - Perfluorocarbon emulsion nanodroplets containing iron oxide nanoparticles (IONPs) within their inner perfluorohexane (PFH) core were prepared to investigate potential use as an acoustically activatable ultrasound contrast agent, with the hypothesis that incorporation of IONPs into the fluorous phase of a liquid perfluorocarbon emulsion would potentiate acoustic vaporization. IONPs with an oleic acid (OA) hydrophobic coating were synthesized through chemical co-precipitation. To suspend IONP in PFH, OA was exchanged with perfluorononanoic acid (PFNA) via ligand exchange to yield fluorophilic PFNA-coated IONPs (PFNA-IONPs). Suspensions with various amounts of PFNA-IONPs (0–15% w/v) in PFH were emulsified in saline by sonication, using 5% (w/v) egg yolk phospholipid as an emulsifier. PFNA-IONPs were characterized with transmission electron microscopy (TEM), transmission electron cryomicroscopy (cryoTEM), and thermogravimetric analysis (TGA) with Fourier transform infrared spectroscopy (FTIR). IONP were between 5 and 10 nm in diameter as measured by electron microscopy, and hydrodynamic size of the PFH nanodroplets were 150 to 230 nm as measured by dynamic light scattering (DLS). Acoustic droplet vaporization of PFH nanodroplets (PFH-NDs) was induced using conversion pulses (100 cycle at 1.1 MHz and 50% duty cycle) provided by a focused ultrasound transducer, and formed microbubbles were imaged using a clinical ultrasound scanner. The acoustic pressure threshold needed for PFH-NDs vaporization decreased with increasing temperature and IONP content. PFH-NDs containing 5% w/v IONP converted to microbubbles at 42 °C at 2.18 MI, which is just above the exposure limits of 1.9 MI allowed by the FDA for clinical ultrasound scanners, whereas 10 and 15% emulsion vaporized at 1.87 and 1.24 MI, respectively. Furthermore, 5% IONP-loaded PFH-NDs injected intravenously into melanoma-bearing mice at a dose of 120 mg PFH/kg, converted into detectable microbubbles in vivo 5 h, but not shortly after injection, indicating that this technique detects NDs accumulated in tumors.
KW - Acoustic droplet vaporization
KW - Iron oxide nanoparticles
KW - Perfluorocarbon emulsion
KW - Perfluorohexane
KW - Ultrasound contrast agents
UR - http://www.scopus.com/inward/record.url?scp=85063457227&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063457227&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2019.03.013
DO - 10.1016/j.jconrel.2019.03.013
M3 - Article
C2 - 30928487
AN - SCOPUS:85063457227
SN - 0168-3659
VL - 302
SP - 54
EP - 62
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -